ArticleAmerican journal of hematology2026

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Sankalp Arora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.